Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.
Good morning, all. Damian here with news of a new biotech venture fund, a bold bet against a billion-dollar deal, and the weight of expectations on Eli Lilly.
The need-to-know this morning
- Biotech earnings last night: Amgen and Gilead Sciences.
- BridgeBio Pharma granted Kyowa Kirin a license to co-develop an experimental drug, called infigratinib, for skeletal dysplasias in Japan. BridgeBio will receive $100 million upfront plus royalties on sales if approved.
A biotech VC playing the long game
A trio of biotech venture capitalists have raised $310 million for a new fund that will take it slow, disbursing its money over the course of 20 years, double the standard timeframe for industry VCs.
About the Author Reprints
To submit a correction request, please visit our Contact Us page.
STAT encourages you to share your voice. We welcome your commentary, criticism, and expertise on our subscriber-only platform, STAT+ Connect